Aerosol performance of large respirable particles of amikacin sulfate produced by spray and freeze drying techniques

Current Drug Delivery

Volumn 6, Issue 1, 2009, Pages 8-16

  Padhi, Bijay K ^a   Chougule, Mahavir B ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Aerosol performance; Large respirable particles; Topography; Traits

Indexed keywords

AMIKACIN; LEUCINE; PHOSPHATIDYLCHOLINE; POLOXAMER;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; FREEZE DRYING; PARTICLE SIZE; PRIORITY JOURNAL; SOLID STATE; SPRAY DRYING;

AEROSOLS; AMIKACIN; CAPSULES; FREEZE DRYING; PARTICLE SIZE; TECHNOLOGY, PHARMACEUTICAL;

EID: 61849164641     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720109787048267     Document Type: Article

References (24)

1. Anderson, P.J.; Blanchard, J.D.; Brain, J.D.; Feldman, H.A.; McNamara, J.J.; Heyder, J. Effect of cystic fibrosis on inhaled aerosol boluses. Am. Rev. Respir. Dis., 1989, 140, 1317-24.
2. Patton, J. Mechanisms of macromolecule absorption by the lung. Adv. Drug Deliv. Rev., 1996, 19, 3-36.
3. Rubio, T.T. Infection in patients with cystic fibrosis. Am. J. Med., 1986, 81(Suppl. 1A), 73-7.
4. Van Klingeren, B. Antibiotic resistance in Pseudomonas aeruginosa, Hemophilus influenzae and Staphylococcus. Chest, 1988, 94 (Suppl. 2), 103s-9.
5. Mukhopadhyay, S.M.; Singh, J.I.; Cater, S.; Ogston, M.F.; Olver, R.E. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis, a meta-analysis of benefits and risks. Thorax, 1996, 51, 364-8.
6. Ramsey, B.W.; Pepe, M.S.; Quan, J.M.; Otto, K.L.; Montgomery, A.; Williams-Warren, J.; Vasiljev, K.M.; Borowitz, D.; Bowman, C.M.; Marshall, B.C.; Marshal, S.I.; Smith, A.L. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med., 1999, 340, 23-30.
7. Boat, T.F. Cystic fibrosis. Textbook of Respiratory Medicine. In Textbook of Respiratory Medicine. W.B. Saunders, Philadelphia. 1988, pp. 1126-52.
8. Kepron, W. Cystic fibrosis in the young adult. Med. North Am., 1996, March, 28-32.
9. Hoiby, N.; Friis, B.; Jensen, K.; Koch, C.; Moller, N.E.; Stovring, S.; Szaff, M. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr., 1982, 301, 75-100.
10. Goldman, J.M.; Bayston, S.M.; O'Connor, S.; Meigh, R.E. Inhaled micronized gentamicin powder, a new delivery system. Thorax, 1990, 45, 939-40.
11. Labiris, R.N.; Crowther, A.M.; Holbrook, H.; Crystyn, S.M.; MacLeod, M.T. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Newhouse. Am. J. Respir. Crit. Care Med., 1999, 160, 1711-16.
12. Edwards, D.; Dunbar, C. Bioengineering of therapeutic aerosols. Ann. Rev. Biomed. Eng., 2002, 4, 93-107.
13. Vanbever, R.; Mintzes, J.; Wan, J.; Nice, J.; Chen, D.; Batycky, R.; Langer, R.; Edwards, D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res., 1999, 16, 1735-42.
14. Cynthia, J.; Musante, J.D.; Schroeter, J.A; Rosati, T.M.; Crowder, A.J.; Hickey, T.B.M. Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci., 2002, 91, 1580-90.
15. Zijlstra, G.S.; Hinrichs, W.L.J.; de Boer, A.H.; Frijlink, H.W. The role of particle engineering in relation to formulation and deagglomeration principle in the development of a drypowder formulation for inhalation of cetrorelix. Eur. J. Pharm. Sci., 2004, 23, 139-49.
16. Chambers, H.M.; Sande, M.A. Antimicrobial agents, The aminoglycosides. In Goodman and Gilman's, The Pharmacological basis of therapeutics (9th ed.), McGraw- Hill, New Delhi. 1996.
17. Joshi, M.R.; Misra, A.N. Dry powder inhalation of liposomal ketotifen fumarate, Formulation and characterization. Int. J. Pharm., 2001, 223, 15-27.
18. Chew, N.Y.K.; Chan, H.-K.J. Effect of powder polydispersibility on aerosol generation. J. Pharm. Sci., 2002, 5, 162-68.
19. Bosquillon, C.; Véronique, P.; Vanbever, R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release, 2004, 96, 233-44.
20. Monographs, Medicinal and Pharmaceutical substances, Amikacin sulfate, British Pharmacopoeia. 2004, CD-ROM.
21. Hickey, A.J.; Martonen, T.B.; Yang, Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm. Acta Helv., 1996, 71, 85-190.
22. Larhrib, H.; Martin, G.P.; Prime D.; Marriott, C. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Eur. J. Pharm. Sci., 2003, 19, 211-21.
23. Chew, N.Y.K.; Tang, P.; Chan, H.-K.; Judy, A.R. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm. Res., 2005, 22, 148-52.
24. Chew, N.Y.K.; Chan, H.-K. Use of solid corrugated particles to enhance aerosol performance. Pharm. Res., 2001, 18, 1570-77.